NO924461L - Dipyridamol for behandling av proliferaktive sykdommer - Google Patents

Dipyridamol for behandling av proliferaktive sykdommer

Info

Publication number
NO924461L
NO924461L NO92924461A NO924461A NO924461L NO 924461 L NO924461 L NO 924461L NO 92924461 A NO92924461 A NO 92924461A NO 924461 A NO924461 A NO 924461A NO 924461 L NO924461 L NO 924461L
Authority
NO
Norway
Prior art keywords
treatment
local delivery
diseases
proliferactive
dipyridamol
Prior art date
Application number
NO92924461A
Other languages
English (en)
Norwegian (no)
Other versions
NO924461D0 (no
Inventor
Raymond Francis Kauffman
Jai Pal Singh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO924461D0 publication Critical patent/NO924461D0/no
Publication of NO924461L publication Critical patent/NO924461L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO92924461A 1991-11-21 1992-11-19 Dipyridamol for behandling av proliferaktive sykdommer NO924461L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/795,434 US5270047A (en) 1991-11-21 1991-11-21 Local delivery of dipyridamole for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
NO924461D0 NO924461D0 (no) 1992-11-19
NO924461L true NO924461L (no) 1993-05-24

Family

ID=25165502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924461A NO924461L (no) 1991-11-21 1992-11-19 Dipyridamol for behandling av proliferaktive sykdommer

Country Status (12)

Country Link
US (2) US5270047A (ja)
EP (1) EP0543653A1 (ja)
JP (1) JPH05201862A (ja)
KR (1) KR930009607A (ja)
AU (1) AU661067B2 (ja)
CA (1) CA2083223A1 (ja)
HU (1) HU212422B (ja)
MX (1) MX9206610A (ja)
NO (1) NO924461L (ja)
RU (1) RU2084224C1 (ja)
TW (1) TW252917B (ja)
ZA (1) ZA928832B (ja)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
WO1994016706A1 (en) * 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5521191A (en) * 1994-10-17 1996-05-28 Washington University Method for treatment of arterial stenosis
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US5951586A (en) * 1996-05-15 1999-09-14 Medtronic, Inc. Intraluminal stent
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO1999009912A1 (en) 1997-08-26 1999-03-04 Technion Research And Development Foundation Ltd. Intravascular apparatus and method
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
RU2157199C2 (ru) * 1998-04-03 2000-10-10 Вахрушев Яков Максимович Способ лечения хронического панкреатита
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
JP4898991B2 (ja) 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー 被覆付植込式医療装置
US6168619B1 (en) * 1998-10-16 2001-01-02 Quanam Medical Corporation Intravascular stent having a coaxial polymer member and end sleeves
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP2003520830A (ja) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション 再狭窄および吻合内膜過形成処置のための送達系
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10119680A1 (de) * 2001-04-20 2002-11-14 Boehringer Ingelheim Pharma Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
NZ532310A (en) * 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
US20030083614A1 (en) * 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
AU2003205315A1 (en) * 2002-01-22 2003-09-02 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DK1521603T3 (da) * 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20040162542A1 (en) * 2002-12-03 2004-08-19 Endobionics, Inc. Methods and systems for treating the vasculature with estrogens
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
EP1610823B1 (en) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantable medical device with continuous agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007532187A (ja) 2004-04-06 2007-11-15 サーモディクス，インコーポレイティド 生物活性物質のためのコーティング組成物
MX2008014828A (es) * 2006-05-22 2009-02-06 Combinatorx Inc Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
EP2203174A4 (en) * 2007-09-19 2010-09-29 Combinatorx Inc THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
KR20190056401A (ko) 2016-09-22 2019-05-24 머케이터 메드시스템즈, 인크. 템시롤리무스를 사용하는 재협착의 치료
WO2018218182A1 (en) 2017-05-26 2018-11-29 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
CN110382019B (zh) 2018-03-14 2020-08-25 墨卡托医疗系统公司 用于局部药物递送的医疗器械和医疗方法
WO2021077070A1 (en) * 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
CN118903419A (zh) * 2020-02-10 2024-11-08 广州市妇女儿童医疗中心 Pde抑制剂或其盐在制备用于预防和/或治疗胃肠道疾病的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1208516A (en) * 1982-04-02 1986-07-29 Harvey Wolinsky Methods and apparatus for relieving arterial constrictions
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
WO1990001969A1 (en) * 1988-08-24 1990-03-08 Slepian Marvin J Biodegradable polymeric endoluminal sealing
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
EP0383429B1 (en) * 1989-01-31 1995-11-08 C.R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors

Also Published As

Publication number Publication date
EP0543653A1 (en) 1993-05-26
AU661067B2 (en) 1995-07-13
MX9206610A (es) 1993-05-01
KR930009607A (ko) 1993-06-21
JPH05201862A (ja) 1993-08-10
ZA928832B (en) 1994-05-16
CA2083223A1 (en) 1993-05-22
TW252917B (ja) 1995-08-01
US5314688A (en) 1994-05-24
HUT70034A (en) 1995-09-28
HU9203626D0 (en) 1993-01-28
NO924461D0 (no) 1992-11-19
HU212422B (en) 1996-06-28
US5270047A (en) 1993-12-14
AU2845492A (en) 1993-05-27
RU2084224C1 (ru) 1997-07-20

Similar Documents

Publication Publication Date Title
NO924461L (no) Dipyridamol for behandling av proliferaktive sykdommer
RU92004406A (ru) Дипиридамол для лечения пролиферативных болезней
ATE114972T1 (de) Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
NO20000762D0 (no) Anvendelse av substituerte adeninderivater til behandling av multippel sklerose
AP9901434A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
AU7107496A (en) Protein tyrosine kinase inhibitors for treating osteoarthritis
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
GEP20012419B (en) N6 Heterocyclic Substituted Adenosine Derivatives
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
ATE202140T1 (de) Hemmung der neovaskulasierung durch vegf- spezifische oligonukleotide
SG43768A1 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
IT1139175B (it) Impiego della combinazione di un inibitore della aromatasi con un antiandrogeno per la profilassi e la terapia dell iperplasia della prostata
ATE309843T1 (de) Verwendung von spermatophyte pflanzenextrakte mit immunomoduelierender wirkung
AU6998787A (en) Transglutaminase inhibitors
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
MD960212A (en) Acylfulvene analogs as antitumor remedy
BG101138A (en) The use of glyceryltriacetate for the treatment of onychomycosis
FI922615A0 (fi) Cellcykelberoende reglering av fosforylering av human retinoblastomgenprodukt.
DE69213757D1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
DK0537007T3 (da) Anvendelse af farnesyl-protein-transferase-inhibitorer til fremstilling af et lægemiddel til blokering af neoplastisk transformation af celler fremkaldt af ras-oncogener
ATE42466T1 (de) Verwendung von saccharomyces hefen zur herstellung eines medikaments zur verhuetung oder behandlung von pseudomembrankolitis.
NO962406L (no) Farmasöytisk formulering for profylakse henholdsvis for behandling av en forgiftning ved fosfororganiske kolinesterasehemmere
DK0534621T3 (da) Fremgangsmåde til inhibering af korrosion ved syrebehandling af boringer
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.
DK0658117T3 (da) Behandling af tumorer med neurotrofe faktorer og celleproliferationsinhibitorer